Navitoclax (ABT-263)

Catalog No.S1001

Navitoclax (ABT-263) Chemical Structure

Molecular Weight(MW): 974.61

Navitoclax (ABT-263) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.

Size Price Stock Quantity  
In DMSO USD 400 In stock
USD 120 In stock
USD 200 In stock
USD 370 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 153 Publications

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Description Navitoclax (ABT-263) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.
Targets
Bcl-xL [1]
(Cell-free assay)
Bcl-2 [1]
(Cell-free assay)
Bcl-w [1]
(Cell-free assay)
<=0.5 nM(Ki) <=1 nM(Ki) <=1 nM(Ki)
In vitro

ABT-263 is structurally related to ABT-737; it is a disruptor of Bcl-2/Bcl-xL interactions with pro-apoptotic proteins. Overexpression of the prosurvival Bcl-2 family members is commonly associated with tumor maintenance, progression, and chemoresistance. [1] ABT-263 displays the protection afforded by overexpression of Bcl-2 or Bcl-xL with EC50 values of 60 nM and 20 nM, respectively. [1] A wide range of cellular activity is observed with ABT-263 having a 50% growth inhibition (EC50) of 110 nM against the most sensitive line (H146), whereas its activity in the least sensitive line (H82) results in an EC50 at 22 μM. All four cell lines with EC50 values of <400 nM (H146, H889, H1963, and H1417) are also highly sensitive to ABT-737, and the two most resistant lines (H1048 and H82) are similarly resistant to ABT-263. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
EoL-1-cell M2PJ[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zlTGlEPTB;MD6wNFY3QSEQvF2= M{j2N3NCVkeHUh?=
MV-4-11 NF\uOVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrKcnlTUUN3ME2wMlAyPTh4IN88US=> NUnyNllVW0GQR1XS
NKM-1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHRUld4UUN3ME2wMlAyPjl7IN88US=> MlL6V2FPT0WU
ML-2 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PhcmlEPTB;MD6wNVk5OyEQvF2= M37VRnNCVkeHUh?=
BV-173 NIX3N4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfpTWM2OD1yLkCyN|E1KM7:TR?= MX\TRW5ITVJ?
RS4-11 NFzqWZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTBwMEK1PFch|ryP NXTtVmdsW0GQR1XS
HL-60 M1HIe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTBwMEK5NFgh|ryP MkjEV2FPT0WU
KY821 NF\KcmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\RfGlEPTB;MD6wNlk4PSEQvF2= NUPGfndMW0GQR1XS
ECC10 MkD1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{mxTGlEPTB;MD6wN|c6OiEQvF2= MWHTRW5ITVJ?
NCI-H720 NF3Ze|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrmTWM2OD1yLkC0NFEyKM7:TR?= MVnTRW5ITVJ?
QIMR-WIL M3HmW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4rLNGlEPTB;MD6wOFI5PyEQvF2= NFzsV45USU6JRWK=
KG-1 M2nnemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoS2TWM2OD1yLkC0OFg3KM7:TR?= NGrLRmRUSU6JRWK=
TGW MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPPTWM2OD1yLkC0OlM{KM7:TR?= NYniOGZrW0GQR1XS
ATN-1 MoTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rGR2lEPTB;MD6wOFc{OyEQvF2= MnHpV2FPT0WU
RH-18 NF3vOmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPad5dKSzVyPUCuNFYxPDhizszN MnG5V2FPT0WU
EW-18 M{fCb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDLW5hKSzVyPUCuNFY5PDFizszN NGHtO2FUSU6JRWK=
NB17 NIr1NWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;rNGlEPTB;MD6wO|EzPCEQvF2= NULtWnpvW0GQR1XS
SK-NEP-1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTBwMEeyNVMh|ryP MXLTRW5ITVJ?
P12-ICHIKAWA NFrIfoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;sTWM2OD1yLkC3O|c5KM7:TR?= M1T2RXNCVkeHUh?=
KARPAS-45 MoX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTBwMEe4NVUh|ryP MX\TRW5ITVJ?
EW-3 NX\lXmZCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkSwTWM2OD1yLkC4NFU{KM7:TR?= MYHTRW5ITVJ?
NB13 NGC2XIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlLXTWM2OD1yLkC4NlA{KM7:TR?= Mkm2V2FPT0WU
NCI-H209 MkX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTBwMEi3NFQh|ryP MlLwV2FPT0WU
NCI-H1092 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{SwOmlEPTB;MD6xNFI4PSEQvF2= MmPOV2FPT0WU
NH-12 NV3vUlRQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTLTWM2OD1yLkGwO|Q1KM7:TR?= NF2yPVZUSU6JRWK=
697 MoPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\rflNKSzVyPUCuNVA5OzlizszN MXPTRW5ITVJ?
KE-37 NFLQcotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPPV21KSzVyPUCuNVE{PyEQvF2= MXfTRW5ITVJ?
MOLT-4 NH7DOWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHITVN[UUN3ME2wMlE2OTZ7IN88US=> MlO1V2FPT0WU
CHP-134 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHCTWM2OD1yLkG2N|A3KM7:TR?= MkXmV2FPT0WU
D-283MED M1vJcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPjSYpKSzVyPUCuNVc3QDZizszN NGDiSINUSU6JRWK=
LU-135 M4P2VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTBwMUi1OVIh|ryP M3\mS3NCVkeHUh?=
LU-134-A NXvTTZNkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfUTWM2OD1yLkG4OlcyKM7:TR?= M4f6PHNCVkeHUh?=
EM-2 NVvONJZoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1rYc2lEPTB;MD6xPVkyQCEQvF2= MVLTRW5ITVJ?
LU-139 MlftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vI[WlEPTB;MD6yNFQ6QCEQvF2= M3S5VnNCVkeHUh?=
ALL-PO MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3LMTGlEPTB;MD6yNVk5QCEQvF2= NXTYNpMyW0GQR1XS
NB12 M4\nemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlT5TWM2OD1yLkKzNVE2KM7:TR?= M4\qPHNCVkeHUh?=
KP-N-YN MlzGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\3TWM2OD1yLkKzOVc{KM7:TR?= NVmz[mVjW0GQR1XS
BEN NH3SVIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkSxTWM2OD1yLkKzPVY5KM7:TR?= M2TZNnNCVkeHUh?=
HCC1569 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXwTWM2OD1yLkK1NVA3KM7:TR?= NXj0UG5JW0GQR1XS
HuO9 Mme5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnjTWM2OD1yLkK2O|E2KM7:TR?= MWLTRW5ITVJ?
WM-115 NFfSNotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn70TWM2OD1yLkK3O|M5KM7:TR?= M2TzPXNCVkeHUh?=
CCRF-CEM NHfMN49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvrRZVzUUN3ME2wMlM{PTJ7IN88US=> MV\TRW5ITVJ?
IST-SL1 NIO5c5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;BfoVKSzVyPUCuN|U{PDNizszN MYLTRW5ITVJ?
BE-13 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\kTWM2OD1yLkO2OFU6KM7:TR?= MnOzV2FPT0WU
COR-L88 M3TTS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTBwM{[1OEDPxE1? NV\mWGhQW0GQR1XS
DOHH-2 M4fsc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVu3WWhjUUN3ME2wMlQyODJ|IN88US=> MnrkV2FPT0WU
A704 MlXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4nRZmlEPTB;MD60NlY4KM7:TR?= NFHPcGtUSU6JRWK=
KNS-81-FD MmjlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4ntcmlEPTB;MD60OFAyPyEQvF2= NInCVYtUSU6JRWK=
RPMI-8226 NUTXboZwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTQT4dKSzVyPUCuOFU3PTJizszN M2[z[XNCVkeHUh?=
TGBC24TKB MoDCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDjOo85UUN3ME2wMlQ2Pzd6IN88US=> MlrmV2FPT0WU
NCI-H1304 NWHyNGx{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2nad2lEPTB;MD60OlE2PyEQvF2= MmrEV2FPT0WU
MOLT-13 M1T5NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rDcWlEPTB;MD60OlYyOyEQvF2= NGPKeZJUSU6JRWK=
EW-22 MmHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVjjd|M5UUN3ME2wMlQ3PjdzIN88US=> MWTTRW5ITVJ?
MS-1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fZNGlEPTB;MD60Olk{OyEQvF2= NULCe3ppW0GQR1XS
RMG-I MkfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fWSWlEPTB;MD60PVQ3PCEQvF2= M2fUXXNCVkeHUh?=
NTERA-S-cl-D1 MkPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjKbW1PUUN3ME2wMlUxODF7IN88US=> NEjnV3BUSU6JRWK=
NCI-H1048 M4TE[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XJZWlEPTB;MD61NFk2OyEQvF2= MX;TRW5ITVJ?
SW1417 Mn;NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLMZ|BKSzVyPUCuOVU1OzhizszN MofQV2FPT0WU
DB MljBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXwTWM2OD1yLkW3NFgh|ryP MXHTRW5ITVJ?
MEG-01 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLTOmp[UUN3ME2wMlU5OzJizszN NYLJ[2pZW0GQR1XS
EW-13 NYr4fZFZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIflfJVKSzVyPUCuOVg{PDFizszN MlfrV2FPT0WU
LAMA-84 NWrzd4tvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTBwNUmyNFch|ryP M2TUeXNCVkeHUh?=
J-RT3-T3-5 M3\BTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHoTWM2OD1yLk[wPFA5KM7:TR?= MYnTRW5ITVJ?
MOLT-16 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfsTnBKSzVyPUCuOlUzPjRizszN NIjjOZNUSU6JRWK=
DU-4475 Ml;NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXH4cGl6UUN3ME2wMlY2PDJ5IN88US=> NF;NZmxUSU6JRWK=
HAL-01 MoLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTBwN{K1OFkh|ryP MUDTRW5ITVJ?
RD NVqwfG1JT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3nHRWlEPTB;MD63OVg6QSEQvF2= NVz1eXExW0GQR1XS
OAW-28 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;YWWlEPTB;MD63PFM4KM7:TR?= M2PUcnNCVkeHUh?=
HCC38 NELSU|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjO[npPUUN3ME2wMlgxOTlizszN MoTJV2FPT0WU
NMC-G1 M4C4O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXhTWM2OD1yLkixNVIyKM7:TR?= M{izU3NCVkeHUh?=
EW-16 M{X6SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTzTWM2OD1yLkixN|I5KM7:TR?= MmrSV2FPT0WU
DU-145 M2npPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTBwOEm5NlMh|ryP NV\ZOmlCW0GQR1XS
HPAF-II NFn2U4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3qTWM2OD1yLkmyOlI5KM7:TR?= MmXWV2FPT0WU
A427 MmnyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2[xcWlEPTB;MD65N|AzOiEQvF2= MV\TRW5ITVJ?
PA-1 M2X0NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmK1TWM2OD1yLkm1OlQzKM7:TR?= NYrzOlFHW0GQR1XS
OAW-42 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3L1dmlEPTB;MD65OlE1PiEQvF2= M3[0bHNCVkeHUh?=
L-428 MlXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\yTGlEPTB;MT6wNVI2KM7:TR?= MXXTRW5ITVJ?
COLO-824 M3vJVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXzTHlUUUN3ME2xMlAyPzB6IN88US=> MW\TRW5ITVJ?
P30-OHK M4X5e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;meJJKSzVyPUGuNFQ3QDhizszN M4LmT3NCVkeHUh?=
NCI-H2170 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTFwME[yN{DPxE1? M4L4NnNCVkeHUh?=
HCC2998 NUjLdIUxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;YU4xKSzVyPUGuNFcyOzVizszN NXXjTVNlW0GQR1XS
NB14 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jjO2lEPTB;MT6xN|c1QCEQvF2= NWLhNot{W0GQR1XS
TGBC1TKB NGq2NotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHoe4ljUUN3ME2xMlE1OTV{IN88US=> M{fBUnNCVkeHUh?=
KP-N-YS NXrmeJFoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LpcWlEPTB;MT6xOlI{PiEQvF2= NITx[3hUSU6JRWK=
CAL-120 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLTUWN[UUN3ME2xMlE3PDJ7IN88US=> MljNV2FPT0WU
SBC-1 NWPqPXVTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHU[2NKSzVyPUGuNVkxPTNizszN M1W3SXNCVkeHUh?=
C32 MmnNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nSZWlEPTB;MT6xPVA5QCEQvF2= M1GwR3NCVkeHUh?=
HCC2157 MkPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrQTWM2OD1zLkG5OFk1KM7:TR?= NFv2dFZUSU6JRWK=
COLO-792 M3vabGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnEUJNKSzVyPUGuNlAxPzFizszN NHPIVpFUSU6JRWK=
ES7 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTFwMke5OVEh|ryP MorMV2FPT0WU
HEL M4PjUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYixOIk3UUN3ME2xMlMyODJ7IN88US=> NYH1PGtyW0GQR1XS
ES4 M{KyVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTFwM{S5PVgh|ryP NF36RmNUSU6JRWK=
NCI-SNU-1 NUS2W45OT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTFwM{[1OVUh|ryP MVrTRW5ITVJ?
MDA-MB-415 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zFSGlEPTB;MT6zPFg2KM7:TR?= NY\BfHBuW0GQR1XS
NCI-H2342 NHzo[pdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXCOoR{UUN3ME2xMlQxOjZ7IN88US=> NYjFXFVZW0GQR1XS
NB69 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33GRWlEPTB;MT60OlI4OSEQvF2= MniyV2FPT0WU
D-247MG MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojtTWM2OD1zLkWxNVIzKM7:TR?= M{TZWnNCVkeHUh?=
SCC-4 NET6VWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFn2fW5KSzVyPUGuOVk5QDdizszN NEnhXIhUSU6JRWK=
HuH-7 MnH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1v4dmlEPTB;MT62O|I6OyEQvF2= MUTTRW5ITVJ?
A388 MkjFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\IUGlEPTB;MT62PFczPCEQvF2= NFnkNW9USU6JRWK=
Calu-3 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\nd2VUUUN3ME2xMlcxPjl5IN88US=> NX[yfZZkW0GQR1XS
NCI-H1648 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;l[29wUUN3ME2xMlcyPDF6IN88US=> MVXTRW5ITVJ?
NCI-H2052 NVi4TXNDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3pTWM2OD1zLkeyNlAyKM7:TR?= M3XEfXNCVkeHUh?=
Ramos-2G6-4C10 NXXCO5dRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnGeI54UUN3ME2xMlc{PjV4IN88US=> M{TDV3NCVkeHUh?=
DEL NXfST2pyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlTCTWM2OD1zLke0OlkzKM7:TR?= M4H2RnNCVkeHUh?=
SNU-423 NIDjbIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;YT5hKSzVyPUGuO|gyPTdizszN M4nqOnNCVkeHUh?=
COR-L23 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTFwN{m4O|Qh|ryP MnT6V2FPT0WU
OMC-1 NGrVepBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTFwOE[wNVYh|ryP MUHTRW5ITVJ?
EW-11 NV;KN|ZmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfxU4lKSzVyPUGuPVU3PTdizszN NInxdppUSU6JRWK=
HSC-3 NYriclAxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7lOnJKSzVyPUGuPVY{PjVizszN NIPUT|VUSU6JRWK=
MLMA MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTFwOU[2O|ch|ryP NETYWnJUSU6JRWK=
RCM-1 MofIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTJwMECzPVkh|ryP MlHLV2FPT0WU
MFE-280 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7aTWM2OD1{LkCyPFQ5KM7:TR?= MnPpV2FPT0WU
ES8 NHzlR5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVzjc4d6UUN3ME2yMlI2PDdzIN88US=> MoDXV2FPT0WU
TE-11 NFLTOnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\YTWM2OD1{LkK5OFc{KM7:TR?= Ml3QV2FPT0WU
HuO-3N1 M{fz[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmmwTWM2OD1{LkS4O|gh|ryP NUGwWmZRW0GQR1XS
MHH-NB-11 Mk\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWT1[Y5lUUN3ME2yMlUyOTV6IN88US=> NFu4TFVUSU6JRWK=
TGBC11TKB Mli3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPLN2hJUUN3ME2yMlU4PjhzIN88US=> NUfyemlGW0GQR1XS
HOP-92 NWTxWnEyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTJwNUi3OFMh|ryP Mmr5V2FPT0WU
IGR-1 NUjHbGd2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTJwNkKwN|Uh|ryP NXGxZo1RW0GQR1XS
GOTO NWHjUIpCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTJwNkWzO|ch|ryP NXmyT|NzW0GQR1XS
NCI-H1650 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTDZ5RNUUN3ME2yMlczOjF3IN88US=> NUfOUZZFW0GQR1XS
NCI-H1581 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfNfIZKSzVyPUKuO|k3QDFizszN NFvQfmZUSU6JRWK=
NCI-H2405 NGGx[lNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXvTWM2OD1{LkiyO|gzKM7:TR?= NHnOZoFUSU6JRWK=
U-118-MG NH7iZm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTJwOU[0PVEh|ryP MmrWV2FPT0WU
DoTc2-4510 M4nHVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfFd3BKSzVyPUOuNFE1OTdizszN NWXGOpdNW0GQR1XS
NCI-H596 MoHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWf2bIV[UUN3ME2zMlA1QTl5IN88US=> M{W1OnNCVkeHUh?=
MPP-89 NHPIOVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmTuTWM2OD1|LkC1OlY3KM7:TR?= MoPWV2FPT0WU
GCIY MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmS3TWM2OD1|LkKwOFkyKM7:TR?= MljoV2FPT0WU
SW626 M{LSO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLzTWM2OD1|LkK0OVQ{KM7:TR?= MYjTRW5ITVJ?
OCI-AML2 MoH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTNwM{GyO|Ih|ryP NV7hOGFYW0GQR1XS
NBsusSR NX36dVdwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTNwM{S5N|gh|ryP NGH4Rm1USU6JRWK=
AN3-CA NWDkcIs2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTNwNESyN|gh|ryP MkHTV2FPT0WU
EFM-19 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfKUIZTUUN3ME2zMlQ5OzN7IN88US=> NF72dZJUSU6JRWK=
RVH-421 NWXmTZNRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUi4dIRvUUN3ME2zMlU3QDd5IN88US=> NGDTVHhUSU6JRWK=
5637 M1;yVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTTTJczUUN3ME2zMlYyOTB|IN88US=> MmjwV2FPT0WU
PANC-08-13 MljES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTNwNkO0O|Ih|ryP M{\zW3NCVkeHUh?=
H9 NVHMS4htT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2OycmlEPTB;Mz62O|E1PCEQvF2= MWfTRW5ITVJ?
KARPAS-299 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTNwNkezOlEh|ryP NYjBV3NNW0GQR1XS
TE-5 M33TUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHNTWM2OD1|LkewO|A6KM7:TR?= MVvTRW5ITVJ?
NOS-1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTNwN{m4N|Qh|ryP MYnTRW5ITVJ?
HH NXmxZlFQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEnYPYVKSzVyPUOuPFM5PjhizszN NYnnUIpnW0GQR1XS
769-P NEfnNVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvjO5lKSzVyPUOuPFk2OSEQvF2= Mn;vV2FPT0WU
CHP-212 M1nhN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmCwTWM2OD1|LkmyOVQ6KM7:TR?= MkPZV2FPT0WU
NCI-H82 MoPTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLqTWM2OD1|Lkm1PVM3KM7:TR?= NUHCbWJDW0GQR1XS
Mo-T NEKzUlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTRwMESzNVIh|ryP NHfTeFZUSU6JRWK=
BB65-RCC MonWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDFTWM2OD12LkC0N|k6KM7:TR?= Mor4V2FPT0WU
SW1990 NWLJ[Jh5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLDSpBwUUN3ME20MlA2QTB6IN88US=> NGWxdY1USU6JRWK=
LK-2 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3:wcGlEPTB;ND6xNVI6OyEQvF2= Mnq3V2FPT0WU
ES5 NEfTOIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXFe5ZKSzVyPUSuNVM6QDVizszN M2LBfnNCVkeHUh?=
JVM-3 Mln6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn20TWM2OD12LkG4NlIzKM7:TR?= NIXYVmpUSU6JRWK=
RPMI-7951 M3\4SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrRTWM2OD12LkKyOFE{KM7:TR?= M2\vVHNCVkeHUh?=
Calu-6 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3UcFZvUUN3ME20MlI4QDhzIN88US=> MWjTRW5ITVJ?
LC-2-ad MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTRwMkm1Olgh|ryP NGrjVYFUSU6JRWK=
SW954 NIfhPZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXrTWM2OD12LkK5OlYh|ryP M4P2e3NCVkeHUh?=
H-EMC-SS NFf6NHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTRwM{G4N|Eh|ryP M1LDNXNCVkeHUh?=
ES3 MkfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVToO451UUN3ME20MlM2PDRzIN88US=> MVnTRW5ITVJ?
no-11 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTRwM{W1OVQh|ryP NUD3cY5rW0GQR1XS
LAN-6 NYm2eW1PT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3yyVGlEPTB;ND60OVE5QSEQvF2= MlTDV2FPT0WU
FTC-133 NELPbnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUSxSY42UUN3ME20MlU{QTVizszN NUDzZoF1W0GQR1XS
8505C MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlH6TWM2OD12LkW0NlMh|ryP MmfPV2FPT0WU
SW620 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTRwNUewOVch|ryP NX7SU3ZtW0GQR1XS
BCPAP NHHFOFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTRwNkO0PFEh|ryP M4DuTHNCVkeHUh?=
SK-LU-1 NWHzcVZWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlu4TWM2OD12Lk[2NFg6KM7:TR?= M{PITHNCVkeHUh?=
NCI-H1623 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEe5VoxKSzVyPUSuO|AzOjhizszN MmHoV2FPT0WU
C2BBe1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTOWZhqUUN3ME20Mlc1ODB6IN88US=> MnvDV2FPT0WU
GP5d NXXVfXhOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofFTWM2OD12Lke4N|g5KM7:TR?= MlXrV2FPT0WU
NB6 NGexOHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTRwOE[yNFQh|ryP NVTaVZZ{W0GQR1XS
MDA-MB-157 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\iXmlEPTB;ND64PFc3KM7:TR?= NGDpNmhUSU6JRWK=
UMC-11 MnjDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDzR3RKSzVyPUSuPFg6PjRizszN MlqxV2FPT0WU
HCC1419 NWTIOpN3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PKdmlEPTB;ND65NFA3OyEQvF2= M2DPOHNCVkeHUh?=
NCI-H2029 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnKPW92UUN3ME20Mlk1OTh3IN88US=> NWS1fnM4W0GQR1XS
LXF-289 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3H3c2lEPTB;NT6wN|cyQSEQvF2= MkXsV2FPT0WU
KINGS-1 NVi1fmQ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYThZYQ4UUN3ME21MlA4PzR2IN88US=> NFmxWGFUSU6JRWK=
HD-MY-Z NVXMSnliT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1HYS2lEPTB;NT6yN|k3QSEQvF2= MVvTRW5ITVJ?
ESS-1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\wXGlEPTB;NT6yOVU6PyEQvF2= NV3FT|BSW0GQR1XS
GI-1 M4mzemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{HqfWlEPTB;NT6yO|kzPiEQvF2= M4f0R3NCVkeHUh?=
RPMI-2650 Ml2zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{fnRmlEPTB;NT6zOlE3KM7:TR?= M{jzT3NCVkeHUh?=
IA-LM NUjXNI02T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInqfo1KSzVyPUWuN|k5PzFizszN NGLxT4pUSU6JRWK=
KP-4 NGLkRnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWGwfoFzUUN3ME21MlQ3OzN2IN88US=> MorUV2FPT0WU
G-402 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jKVGlEPTB;NT61NVg3PSEQvF2= MnnUV2FPT0WU
OS-RC-2 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYCzfJo4UUN3ME21MlUzPjB2IN88US=> NYCxSmlJW0GQR1XS
NCI-H1155 MlTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnGzTWM2OD13LkW0PVU2KM7:TR?= M3z2fnNCVkeHUh?=
OE19 M3PLb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjQTWM2OD13Lk[4OlI1KM7:TR?= M17E[3NCVkeHUh?=
U-2-OS M2OyU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUGyNIpzUUN3ME21Mlg6ODF|IN88US=> NFjENpNUSU6JRWK=
SCC-15 NHHTN2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTVwOUO2OlIh|ryP NWjJVFc1W0GQR1XS
NCI-H630 M2jVPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfYNI9KSzVyPUWuPVk1ODRizszN NFzXR4hUSU6JRWK=
PFSK-1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnNPHhKSzVyPU[uNFUzPTlizszN NWLoNY5nW0GQR1XS
NCI-H1770 NIS1d5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV3H[FRkUUN3ME22MlIxQDd2IN88US=> NHT0bIJUSU6JRWK=
SK-MEL-3 MmflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4WyfWlEPTB;Nj60NlkyPSEQvF2= M2LJNnNCVkeHUh?=
LB1047-RCC M3i2UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfKTWM2OD14LkS3OlI2KM7:TR?= MkTyV2FPT0WU
NCI-H446 NIrmUXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfoSZZKSzVyPU[uOlI6OjVizszN MVfTRW5ITVJ?
SW780 M1TVVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXFTWM2OD14LkewNVg2KM7:TR?= NHK2N5pUSU6JRWK=
NEC8 MoH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYW5bHRvUUN3ME22Mlc3PjNizszN M2TVTHNCVkeHUh?=
NOMO-1 M3vEdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LPeWlEPTB;Nj63PFEyOSEQvF2= NXvGbWhRW0GQR1XS
COLO-668 NHz0fpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjUOolGUUN3ME22Mlg1Ozh5IN88US=> NYm5Uol[W0GQR1XS
MC116 MnPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlP2TWM2OD14LkmzPFk4KM7:TR?= NXyzWIlEW0GQR1XS
HCC1937 NF[5boNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjVeJRKSzVyPU[uPVkzPTFizszN NWDHd29SW0GQR1XS
NCI-N87 M3;1dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY[1Z|RWUUN3ME23MlE6Ojl|IN88US=> MlS0V2FPT0WU
COLO-320-HSR Ml7QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mkn3TWM2OD15LkKyO|M5KM7:TR?= MmLVV2FPT0WU
HCC1806 NVi3d3dbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTdwMk[wOFQh|ryP NHP3Sm5USU6JRWK=
OVCAR-3 M2rvT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH[5OItKSzVyPUeuN|MxOzhizszN MYPTRW5ITVJ?
NUGC-3 MojVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfkclBHUUN3ME23MlM6Pjl2IN88US=> M2Pxe3NCVkeHUh?=
SW1783 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PpSGlEPTB;Nz60N|E4PSEQvF2= MUPTRW5ITVJ?
GCT Mo\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2TWdGlEPTB;Nz61OlkxPiEQvF2= NHHIN25USU6JRWK=
NCI-H2126 NXu4bZFTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTdwN{O2NlUh|ryP NELxWIhUSU6JRWK=
MEL-HO NITtVIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTdwN{ewOVQh|ryP MmLuV2FPT0WU
CAPAN-1 M2Tt[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrsfWFTUUN3ME23Mlc4OzV5IN88US=> NVLVbZduW0GQR1XS
SW756 NG\VS5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPGTWM2OD15Lke4N|M{KM7:TR?= MYrTRW5ITVJ?
SKG-IIIa NXSxbVRnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4T2e2lEPTB;Nz64NVg6OiEQvF2= MnfOV2FPT0WU
HCE-T M3;1ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\OS4JKSzVyPUeuPFc4QDNizszN MmjyV2FPT0WU
Ca-Ski NUT4cGNnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zYe2lEPTB;Nz65PVM5OyEQvF2= M4P5XXNCVkeHUh?=
COLO-684 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITLNZlKSzVyPUiuNFE5OThizszN MkPqV2FPT0WU
KYSE-70 M3XSS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjjWpVOUUN3ME24MlA4PzJ7IN88US=> MWXTRW5ITVJ?
TI-73 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3r6TWlEPTB;OD6yOVg2OSEQvF2= M1\CNHNCVkeHUh?=
BT-20 NIDyN29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;QeGlEPTB;OD6yOlA2OiEQvF2= NEfRb|FUSU6JRWK=
MHH-ES-1 NFTCU2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlSxTWM2OD16LkWxPFM1KM7:TR?= NFW2[HJUSU6JRWK=
TE-12 NEW2XXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jR[mlEPTB;OD61PVk{OSEQvF2= NFzYNZpUSU6JRWK=
YH-13 M{nObmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jJZWlEPTB;OD62NVAxQCEQvF2= M4TtSHNCVkeHUh?=
SF126 MkP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUTFWWdxUUN3ME24Mlg{QDZ3IN88US=> MVXTRW5ITVJ?
J82 NWKzfJJGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfOTWM2OD16LkmwNFM5KM7:TR?= NV\6RWVvW0GQR1XS
RCC10RGB NUTXUHZ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnz[4oxUUN3ME24Mlk6PTZzIN88US=> MUDTRW5ITVJ?
SK-UT-1 Moe3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHKzZ4ZKSzVyPUmuNFQ6PDVizszN MWfTRW5ITVJ?
LB2241-RCC M2THRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTlwMUmxN|ch|ryP NHjxR5RUSU6JRWK=
LB996-RCC MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\3R5hKSzVyPUmuNVk5QSEQvF2= M3LBR3NCVkeHUh?=
EPLC-272H M3TJUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTlwM{e2OVch|ryP NFz2b2pUSU6JRWK=
CTV-1 NHr2fmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTlwNU[1N|Ih|ryP MVPTRW5ITVJ?
HSC-2 M3rNN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTlwNUe1OUDPxE1? MnX3V2FPT0WU
SK-MEL-28 NELVWnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVr5XmVTUUN3ME25MlYyQDl|IN88US=> M3nP[HNCVkeHUh?=
MMAC-SF NVHF[o56T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPoTWM2OD17Lk[4O|Uh|ryP MWnTRW5ITVJ?
CP50-MEL-B MoXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7nRYlKSzVyPUmuO|U4QDJizszN MVPTRW5ITVJ?
HT-1080 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTlwN{e3N|kh|ryP NHrjOXhUSU6JRWK=
HEC-1 M13me2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXPcmJKSzVyPUGwMlM{PTJizszN MULTRW5ITVJ?
AGS NIC0fFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3THdWlEPTB;MUCuN|c1KM7:TR?= M3vTUHNCVkeHUh?=
GAMG M{T0fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTFyLkWxOlIh|ryP NF7xZXFUSU6JRWK=
SW48 MnXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLHNWFKSzVyPUGwMlUyQDlizszN NVjoTZVDW0GQR1XS
U031 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVuzNGVWUUN3ME2xNE42QTB6IN88US=> NVi1OnlWW0GQR1XS
OVCAR-5 NGK3VY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLrdmJKSzVyPUGwMlY1OjlizszN M{L3ZnNCVkeHUh?=
SF295 NXnsO|FiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPxTWM2OD1zMD62O|A1KM7:TR?= Mn[0V2FPT0WU
BHT-101 M2P2NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTFyLkexO|ch|ryP MVPTRW5ITVJ?
VMRC-RCZ NVf0S4d7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\BTWM2OD1zMT6zNlAyKM7:TR?= MnLUV2FPT0WU
ACHN MkPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnzdZE{UUN3ME2xNU41OjFzIN88US=> MV3TRW5ITVJ?
NCI-H526 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nOUWlEPTB;MUGuOVA1OyEQvF2= NUDUNo83W0GQR1XS
MN-60 NYLDUJlCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\wSWlEPTB;MUGuOVM6KM7:TR?= M1jFRXNCVkeHUh?=
NCI-H2291 M1vtdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2ja[mlEPTB;MUGuOVQ3PiEQvF2= MUXTRW5ITVJ?
SCC-25 M1;Vfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnXfVRKSzVyPUGxMlc2PTZizszN NIjQ[FRUSU6JRWK=
SK-MEL-2 MoH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUL4W4wyUUN3ME2xNU44PjN5IN88US=> MlPuV2FPT0WU
SN12C MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfrT2p7UUN3ME2xNU46OzV3IN88US=> Mn7uV2FPT0WU
NCI-H69 MkewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH32fGdKSzVyPUGyMlQzOzRizszN M{\EcHNCVkeHUh?=
ME-180 NGHreItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojtTWM2OD1zMj63NFU1KM7:TR?= M3LEVnNCVkeHUh?=
MC-IXC NIWzWFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTF{Lke1NVgh|ryP MnKwV2FPT0WU
NCI-H2347 M2i1Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTF{Lke2NVQh|ryP NX:zVHM2W0GQR1XS
M059J NV\J[pZlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIm2PI9KSzVyPUGyMlc4OjdizszN NWnMbmJNW0GQR1XS
A2058 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\lTIhTUUN3ME2xNk45PjhzIN88US=> Mn\mV2FPT0WU
VA-ES-BJ M{LxS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjXOo1KSzVyPUGyMlg4QDVizszN MnrLV2FPT0WU
Ca9-22 Mn3PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4D5OmlEPTB;MUKuPVQ2OSEQvF2= MmLJV2FPT0WU
KNS-42 M1TtUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTF{Lkm5PFQh|ryP M1uwenNCVkeHUh?=
LoVo NG\RXmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTF|LkKzNVMh|ryP MmfMV2FPT0WU
AM-38 MnewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTF|LkK1OlYh|ryP MmXUV2FPT0WU
NB5 Mm\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDW[lVZUUN3ME2xN{4{PzV{IN88US=> NFLCcZBUSU6JRWK=
L-363 M1r6[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrDNml2UUN3ME2xN{41ODN|IN88US=> MoLlV2FPT0WU
SK-MEL-30 M3HWXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7TTWM2OD1zND6wOlQ2KM7:TR?= M4XzcHNCVkeHUh?=
NCI-H1563 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvNT4JKSzVyPUG0MlYxOzlizszN MnntV2FPT0WU
NCI-H2228 NFrIR3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fwd2lEPTB;MUSuOlA4PyEQvF2= M2OyTnNCVkeHUh?=
MFM-223 NHTjcHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIKybI1KSzVyPUG1MlE5OTNizszN NIXic4pUSU6JRWK=
LB831-BLC M1vwO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHGTWM2OD1zNT6yO|Y4KM7:TR?= NFS4[pBUSU6JRWK=
SW872 NWjucoJST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rrcWlEPTB;MUWuN|A5PiEQvF2= M2nienNCVkeHUh?=
NCI-H522 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3nCbWlEPTB;MUWuN|MxPiEQvF2= M{HhUHNCVkeHUh?=
EW-1 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTF3LkW0OlIh|ryP MXHTRW5ITVJ?
HN M1\DPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXy3b|NVUUN3ME2xOU42QTR{IN88US=> MorPV2FPT0WU
SW837 NIn1PIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XGV2lEPTB;MUWuO|g1PyEQvF2= MmP1V2FPT0WU
SCC-9 NEnldFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fEbGlEPTB;MUWuPFEyPCEQvF2= NGO1XlZUSU6JRWK=
MKN7 NE\6W3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHzT2RKSzVyPUG1Mlk4OzJizszN MXvTRW5ITVJ?
KYSE-410 M2XSOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{eyRmlEPTB;MU[uOVkyKM7:TR?= MYTTRW5ITVJ?
SK-N-DZ MkDPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVv0U5NPUUN3ME2xOk43OTF4IN88US=> MWPTRW5ITVJ?
COR-L105 NYm1[3Y2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTF4Lk[1Nlgh|ryP Mof6V2FPT0WU
LB2518-MEL NEnOdoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEj2XlJKSzVyPUG2Mlg{QDlizszN NHy0fWlUSU6JRWK=
OVCAR-4 NIXJW3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHtNYVKSzVyPUG2Mlg5PjJizszN NGnxXIFUSU6JRWK=
TK10 M4[5W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXe1NohYUUN3ME2xOk46PDd|IN88US=> MWrTRW5ITVJ?
KNS-62 Mkm5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHrNHpKSzVyPUG2Mlk4PzdizszN NInQUopUSU6JRWK=
RPMI-8866 NVu3N28{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LvTGlEPTB;MUeuNVc{OiEQvF2= MlfOV2FPT0WU
HuP-T4 MnPTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHK0SGNKSzVyPUG3MlI1QTVizszN Ml3zV2FPT0WU
CGTH-W-1 MnLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEG0W4lKSzVyPUG3MlUzOTlizszN M2TqUXNCVkeHUh?=
T-24 NGDIT3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHUTWM2OD1zNz61N|Q4KM7:TR?= NIfWcFFUSU6JRWK=
HT-3 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTZW3VKSzVyPUG3MlU6OTRizszN NEC2WHdUSU6JRWK=
KS-1 NXLvPVdjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjLTWM2OD1zNz62O|Mh|ryP NXPvc5doW0GQR1XS
NCI-H1792 M3nsTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHH3TI9KSzVyPUG3Mlc6QCEQvF2= NVPleZlqW0GQR1XS
ABC-1 M3LEcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nVS2lEPTB;MUeuPFE1OSEQvF2= Mlf3V2FPT0WU
BPH-1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DKVmlEPTB;MUiuNVY5PSEQvF2= MUjTRW5ITVJ?
A431 M33ZSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorjTWM2OD1zOD60NVI4KM7:TR?= NXzJdYk{W0GQR1XS
T98G MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTF6LkWxOVch|ryP NF3tOnBUSU6JRWK=
BHY MmrQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\UVWlEPTB;MUiuPFY6KM7:TR?= MYLTRW5ITVJ?
Capan-2 M1S1UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvhWopKSzVyPUG4MlkxPzhizszN MUTTRW5ITVJ?
MDA-MB-175-VII MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTF6LkmyNFkh|ryP NF30XVNUSU6JRWK=
CAL-27 MlK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTF7LkC0PFch|ryP NIjCfYVUSU6JRWK=
AsPC-1 NHPTbnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTF7Lki2OVch|ryP NGrQRWxUSU6JRWK=
KU812 M2DJW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3u4SmlEPTB;MUmuPVU4OyEQvF2= MWfTRW5ITVJ?
NCI-H441 MnzsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFL1UoVKSzVyPUKwMlAxOSEQvF2= MnLoV2FPT0WU
Mewo MmXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTJyLkGyPFgh|ryP M1zZN3NCVkeHUh?=
SK-MEL-24 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3T6SGlEPTB;MkCuNVQ4PyEQvF2= NUjJO2JIW0GQR1XS
NCI-H727 NUXLdGhpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3SZ5dXUUN3ME2yNE4zPzB2IN88US=> NXPjemg6W0GQR1XS
EKVX M16zcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\OTWM2OD1{MD62NFYh|ryP M2nGNHNCVkeHUh?=
RT-112 M3fzV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7HTWM2OD1{MD62NVIzKM7:TR?= NYLEepRkW0GQR1XS
CAMA-1 NWrK[JJ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWX0VZZxUUN3ME2yNE46QDB|IN88US=> Mn7PV2FPT0WU
SW900 M2DLfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvPTWM2OD1{MT6wNVQ6KM7:TR?= NHewb|lUSU6JRWK=
NCI-H23 M3nueGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XvXWlEPTB;MkGuNVI4PyEQvF2= M1Lic3NCVkeHUh?=
SK-PN-DW M4rj[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTJzLkG2OFkh|ryP M{nx[XNCVkeHUh?=
BB30-HNC MnmyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkPqTWM2OD1{MT6yO|Q2KM7:TR?= NXG5fo9OW0GQR1XS
VM-CUB-1 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYqyfY83UUN3ME2yNU4{PTN4IN88US=> M{\jPXNCVkeHUh?=
IST-MEL1 NUjs[JJtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vVO2lEPTB;MkGuN|Y6OiEQvF2= NXjTWoN6W0GQR1XS
CTB-1 NFXOXVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorITWM2OD1{MT60O|U2KM7:TR?= MYTTRW5ITVJ?
LCLC-103H M1O1NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXeyc29mUUN3ME2yNk4yPTh{IN88US=> MYfTRW5ITVJ?
PANC-03-27 MlLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2q3T2lEPTB;MkKuOVE3QSEQvF2= MXfTRW5ITVJ?
HTC-C3 M3fNbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\WTWM2OD1{Mj61OVU2KM7:TR?= MXzTRW5ITVJ?
TE-8 MkG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mof4TWM2OD1{Mz6yOVY2KM7:TR?= MlzvV2FPT0WU
NCI-H292 MoXnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTJ3LkO1N|Yh|ryP MorxV2FPT0WU
COLO-680N Mm\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPUfW5KSzVyPUK1MlY{OjlizszN NWftXlFkW0GQR1XS
KYSE-520 Mln1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLyTWM2OD1{NT62OFQh|ryP NIrQ[JVUSU6JRWK=
NB10 M1HRZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvtcolKSzVyPUK2MlMyOTdizszN NEPme5dUSU6JRWK=
NCI-H661 NVP6flNiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlq0TWM2OD1{Nj60O|E{KM7:TR?= MkTFV2FPT0WU
GMS-10 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TRfGlEPTB;Mk[uPFY{QCEQvF2= NIfYTFBUSU6JRWK=
NCI-H2122 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2PJ[WlEPTB;Mk[uPVk6QCEQvF2= MYnTRW5ITVJ?
OVCAR-8 NEDndmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rBPGlEPTB;MkeuNFY{QCEQvF2= M1KxdHNCVkeHUh?=
DJM-1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjvbGRHUUN3ME2yO{4yPDV2IN88US=> NULncnN6W0GQR1XS
UACC-893 M2fjPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXGXVZtUUN3ME2yO{46QDd6IN88US=> MmjZV2FPT0WU
C8166 NHjVfXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvITWM2OD1{OD62PVM5KM7:TR?= MnTUV2FPT0WU
NCI-H1693 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTJ6Lk[5O|Uh|ryP NVPJe2VHW0GQR1XS
TYK-nu M2q2Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHxSZhkUUN3ME2zNE4xOzR3IN88US=> NHHkUVhUSU6JRWK=
SW1710 MonGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFH2cJJKSzVyPUOwMlEzPiEQvF2= M2\GPHNCVkeHUh?=
A375 MnXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LQOWlEPTB;M{CuN|I1OyEQvF2= MWHTRW5ITVJ?
HMV-II NV3zTWNST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MomxTWM2OD1|MT6zOVkzKM7:TR?= MUDTRW5ITVJ?
NCI-H2087 NXyzU5p2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkS1TWM2OD1|MT62N|UzKM7:TR?= NX;5XWN{W0GQR1XS
CAL-54 NFLB[mJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTNzLkeyOFEh|ryP NYLqZ3ZOW0GQR1XS
HCC70 MnnxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTN{LkGzPFch|ryP NYHuS4V6W0GQR1XS
ES1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPYdGtKSzVyPUOyMlMxPjJizszN MXrTRW5ITVJ?
NCI-H1355 MlfTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPaTWM2OD1|Mz6yNFQh|ryP NEnHRZBUSU6JRWK=
CFPAC-1 NYK5U4VLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\tTWM2OD1|Mz6yN|MzKM7:TR?= NVTH[VA2W0GQR1XS
MKN28 MnrTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYn2ZWF{UUN3ME2zN{4{QDB7IN88US=> NFvJOJZUSU6JRWK=
HDLM-2 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVvUVlNKUUN3ME2zN{43QTNzIN88US=> NVvyb5A2W0GQR1XS
PANC-10-05 NWDEXZJIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoD4TWM2OD1|ND6xNFE1KM7:TR?= M4G0XnNCVkeHUh?=
SAS MlnES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmW3TWM2OD1|ND60OVY2KM7:TR?= NV;lTJVMW0GQR1XS
HCC1395 MnvYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjSTWM2OD1|ND63NVg3KM7:TR?= NYrNTpBrW0GQR1XS
8305C NXnU[WpJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojSTWM2OD1|NT64OFE2KM7:TR?= NF\IXI1USU6JRWK=
KM12 M{[y[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTN4Lke1OFch|ryP M4T3WnNCVkeHUh?=
SW1116 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjoRoRKSzVyPUO3MlU6QTJizszN NGPmcXNUSU6JRWK=
SK-MEL-1 NILKOXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknJTWM2OD1|OD6zN|g6KM7:TR?= MYHTRW5ITVJ?
HCC2218 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPUPFJKSzVyPUO4MlY2OTlizszN MVLTRW5ITVJ?
T84 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTN6Lke0NFkh|ryP MkftV2FPT0WU
ETK-1 M4CydGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn:xTWM2OD1|OT6wNlIh|ryP M1uxOXNCVkeHUh?=
COLO-800 MlTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPRTWM2OD1|OT6zPFY5KM7:TR?= NGTOeFhUSU6JRWK=
CAL-12T NV;kT4dPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTN7LkWyPFEh|ryP NYLObVdLW0GQR1XS
ACN NHvjOIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3C[WRKSzVyPUSwMlQ6OTFizszN NWDMXpNNW0GQR1XS
SJSA-1 M1HLRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7yTWM2OD12MT6xOVk3KM7:TR?= NYXHUnJSW0GQR1XS
PSN1 MmfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTRzLkG3OFkh|ryP MX7TRW5ITVJ?
D-566MG MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4T6TGlEPTB;NEGuNlA5PiEQvF2= NUHzRVRiW0GQR1XS
EGI-1 NYO2foJTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYD2VFIxUUN3ME20Nk41OjhizszN MkjKV2FPT0WU
A204 M1TXb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHzTWM2OD12Mj62N|g5KM7:TR?= NXm4eJNYW0GQR1XS
Saos-2 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTR{LkizOlkh|ryP NVT1TopsW0GQR1XS
SNU-C2B NXPvVWNMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTR|Lk[4O|gh|ryP MX;TRW5ITVJ?
HLE MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHCfHNJUUN3ME20OE4xQDV4IN88US=> Mki1V2FPT0WU
SW1463 Mnn6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLVTWM2OD12ND65PVcyKM7:TR?= MXHTRW5ITVJ?
DSH1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWq5d2NwUUN3ME20OU4xODN|IN88US=> MmDuV2FPT0WU
MCF7 NX;xVIRpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGryOJBKSzVyPUS1MlUxPTFizszN M4fmcHNCVkeHUh?=
K5 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTR3Lkm0NFUh|ryP NUOzSXppW0GQR1XS
NCI-H358 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDHcG9LUUN3ME20O{4zOTVizszN NGHG[FdUSU6JRWK=
NCI-H2030 M33RZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWe0[HU3UUN3ME20O{4zOzd2IN88US=> NXXOfo96W0GQR1XS
SW948 NF;EXY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjXR|FsUUN3ME20O{41PjRizszN M3O1[XNCVkeHUh?=
BALL-1 NUCwO4pQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoS0TWM2OD12Nz62NVY5KM7:TR?= NU\QdGxDW0GQR1XS
TE-9 NX;Kem5yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEL6do1KSzVyPUS3Mlk2QDFizszN M1i1O3NCVkeHUh?=
SK-N-FI NX23RXJ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjDXWtWUUN3ME20PE4xOzV6IN88US=> NHXVNHZUSU6JRWK=
KALS-1 NUDmfY9MT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIP0SpdKSzVyPUS4MlEzQDlizszN MYTTRW5ITVJ?
HO-1-N-1 M1XuUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\BdGlEPTB;NEiuO|Q1PSEQvF2= MVTTRW5ITVJ?
NCI-H2452 MoHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\4VYRKSzVyPUS5MlEyPTJizszN NFT3e|ZUSU6JRWK=
OC-314 NGnySpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPjenBqUUN3ME20PU43QDN2IN88US=> NGLTcHNUSU6JRWK=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
STAT3 / pSTAT3 / STAT6 / pSTAT6 / Mcl-1 / Cleaved Mcl-1 / Bcl-xl / Bim / puma / Bik / Bax / PARP / c-Myc; 

PubMed: 26811457     


(A) Western blot analysis of expressions of STAT3/p-STAT3 and STAT6/p-STAT6 as well as antiapoptotic members (Bcl-2, Bcl-xL, and Mcl-1) after 48 h of treatments in HDLM-2 cells. (B) Western blot analysis of expressions of proapoptotic proteins (Bim, Puma, Bik, Bax, and p-Bad) as well as caspase cascade molecules (PARP and c-Myc) after 48 h of treatments. β-Actin was used as an input control.

caspase3 / cleaved caspase 3; 

PubMed: 24481442     


(b) (i) N/TERT, (ii) SINCE and (iii) SINEG2 cells were either untreated (0 μM/DMSO) or treated with increasing doses of Navitoclax (ABT-263; 0.025–30 μM) and were incubated for 24 h. Next, cells were collected and whole-cell lysates were prepared and immunoblotted against anti-full-length Caspase 3 (∼35 kDa) antibody, whereas β-actin (∼42 kDa) was used as a protein-loading control. Apoptosis was assessed through detecting the cleaved bands of Caspase-3 (∼19, 17 kDa). 

26811457 24481442
Growth inhibition assay
Cell viability; 

PubMed: 25685063     


(C) Hcc827, (D) H292, and (E) H1993 cells were treated with increasing concentrations of albendazole or mebendazole in the presence of navitoclax (0, 1, 2, and 4 μM). Viability was determined after 1 day.

25685063
In vivo When ABT-263 is administered at 100 mg/kg/day in the H345 xenograft model, significant antitumor efficacy is observed with 80% TGI and 20% of treated tumors indicating at least a 50% reduction in tumor volume. [2] Oral administration of ABT-263 alone causes complete tumor regressions in xenograft models of small-cell lung cancer and acute lymphoblastic leukemia. In xenograft models of aggressive B-cell lymphoma and multiple myeloma where ABT-263 displays modest or no single agent activity, it significantly enhances the efficacy of clinically relevant therapeutic regimens. [2]

Protocol

Kinase Assay:

[1]

- Collapse

Affinity determination:

Binding affinities (Ki or IC50) of ABT-263 against different isoforms of Bcl-2 family are determined with competitive fluorescence polarization assays. The following peptide probe/protein pairs are used: f-bad (1 nM) and Bcl-xL (6 nM), f-Bax (1 nM) and Bcl-2 (10 nM), f-Bax (1 nM) and Bcl-w (40 nM), f-Noxa (2 nM) and Mcl-1 (40 nM), and f-Bax (1 nM) and Bcl-2-A1 (15 nM). Binding affinities for Bcl-xL are also determined using a time-resolved fluorescence resonance energy transfer assay. Bcl-xL (1 nM, His tagged) is mixed with 200 nM f-Bak, 1 nM Tb-labeled anti-His antibody, and ABT-263 at room temperature for 30 min. Fluorescence is measured on an Envision plate reader using a 340/35 nm excitation filter and 520/525 (f-Bak) and 495/510 nm (Tb-labeled anti-His antibody) emission filters.
Cell Research:

[1]

- Collapse
  • Cell lines: SCLC cell lines
  • Concentrations: 0-1 μM
  • Incubation Time: 48 hours
  • Method:

    Human tumor cell lines SCLC cell lines are maintained at 37℃ containing 5% CO2. SCLC cell lines are cultured in RPMI 1640 with 10% fetal bovine serum (FBS), 1% sodium pyruvate, 25 mM HEPES, 4.5 g/L glucose, and 1% penicillin/streptomycin. Leukemia and lymphoma cell lines are cultured in RPMI 1640 supplemented with 10% FBS and 1% penicillin/streptomycin. Cells (1-5×10 4) are treated by ABT-263 for 48 hours in 96-well culture plates in a final volume of 100 μL and cytotoxicity is assessed with the CellTiter Glo assay. In vitro cyto toxicity of ABT-263 is assayed.


    (Only for Reference)
Animal Research:

[1]

- Collapse
  • Animal Models: C.B.-17 scid-bg or C.B.-17 scid mice
  • Formulation: Formulated in 10% ethanol, 30% polyethylene glycol 400, and 60% Phosal 50 PG
  • Dosages: 100 mg/kg/d
  • Administration: Administered via p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (102.6 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+corn oil
For best results, use promptly after mixing.
7mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 974.61
Formula

C47H55ClF3N5O6S3

CAS No. 923564-51-6
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03181126 Recruiting Drug: Navitoclax|Drug: Chemotherapy|Drug: Venetoclax Acute Lymphoblastic Leukemia (ALL)|Lymphoblastic Lymphoma AbbVie November 27 2017 Phase 1
NCT02520778 Recruiting Drug: Navitoclax|Drug: Osimertinib Advanced Lung Non-Squamous Non-Small Cell Carcinoma|EGFR Exon 19 Deletion Mutation|EGFR NP_005219.2:p.L858R|EGFR NP_005219.2:p.T790M|Metastatic Lung Non-Squamous Non-Small Cell Carcinoma|Stage III Lung Non-Small Cell Cancer AJCC v7|Stage IIIA Lung Non-Small Cell Cancer AJCC v7|Stage IIIB Lung Non-Small Cell Cancer AJCC v7|Stage IV Lung Non-Small Cell Cancer AJCC v7 National Cancer Institute (NCI) March 31 2016 Phase 1
NCT02591095 Completed Drug: ABT-263 Platinum-resistant or Refractory Ovarian Cancer Centre Francois Baclesse|ARCAGY/ GINECO GROUP|French Cancer Research Hospital Program January 2016 Phase 2
NCT02079740 Recruiting Biological: Navitoclax|Drug: Trametinib Advanced Malignant Solid Neoplasm|Malignant Female Reproductive System Neoplasm|Metastatic Malignant Solid Neoplasm|Recurrent Lung Carcinoma|Recurrent Malignant Solid Neoplasm|Recurrent Pancreatic Carcinoma|Stage III Lung Cancer AJCC v7|Stage III Pancreatic Cancer AJCC v6 and v7|Stage IV Lung Cancer AJCC v7|Stage IV Pancreatic Cancer AJCC v6 and v7|Unresectable Malignant Solid Neoplasm National Cancer Institute (NCI) March 7 2014 Phase 1|Phase 2
NCT00887757 Completed Drug: ABT-263|Drug: gemcitabine Solid Tumors AbbVie|Genentech Inc. September 2009 Phase 1
NCT00888108 Completed Drug: ABT-263|Drug: Docetaxel Solid Tumor Abbott|Genentech Inc. July 2009 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I would like to deliver S1001 via i.p. injection, can you suggest a vehicle solution?

  • Answer:

    S1001 ABT-263 (Navitoclax) can be dissolved in 5% DMSO+corn oil at 7mg/ml as a clear solution.

  • Question 2:

    Could you tell me if the catalog number S1001 can go through the hemato-encephalic barrier?

  • Answer:

    According to the paper: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3223694/, ABT-263 can not cross brain-blood barrier.

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Related Bcl-2 Products

Tags: buy Navitoclax (ABT-263) | Navitoclax (ABT-263) supplier | purchase Navitoclax (ABT-263) | Navitoclax (ABT-263) cost | Navitoclax (ABT-263) manufacturer | order Navitoclax (ABT-263) | Navitoclax (ABT-263) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID